Analysts forecast that Mateon Therapeutics Inc (NASDAQ:MATN) will announce earnings of ($0.13) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Mateon Therapeutics’ earnings. Mateon Therapeutics reported earnings per share of ($0.14) during the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 2nd.

According to Zacks, analysts expect that Mateon Therapeutics will report full year earnings of ($0.42) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.50) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Mateon Therapeutics.

Mateon Therapeutics (NASDAQ:MATN) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.02.

MATN has been the topic of a number of recent analyst reports. Roth Capital initiated coverage on Mateon Therapeutics in a research report on Thursday, April 20th. They issued a “buy” rating and a $2.00 target price on the stock. Maxim Group reiterated a “buy” rating and issued a $2.00 target price on shares of Mateon Therapeutics in a research report on Thursday, March 16th. Rodman & Renshaw reiterated a “buy” rating and issued a $2.00 target price on shares of Mateon Therapeutics in a research report on Monday, March 13th. Zacks Investment Research cut Mateon Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, May 13th. Finally, HC Wainwright initiated coverage on Mateon Therapeutics in a research report on Monday, March 13th. They issued a “buy” rating and a $2.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Mateon Therapeutics has a consensus rating of “Buy” and a consensus price target of $2.00.

Shares of Mateon Therapeutics (NASDAQ:MATN) traded up 9.9655% on Thursday, reaching $0.3189. 28,740 shares of the company traded hands. The company’s market capitalization is $8.46 million. Mateon Therapeutics has a one year low of $0.28 and a one year high of $0.89. The firm’s 50 day moving average is $0.47 and its 200 day moving average is $0.54.

COPYRIGHT VIOLATION NOTICE: “-$0.13 EPS Expected for Mateon Therapeutics Inc (NASDAQ:MATN) This Quarter” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/03/0-13-eps-expected-for-mateon-therapeutics-inc-nasdaqmatn-this-quarter-updated-updated-updated.html.

About Mateon Therapeutics

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

Get a free copy of the Zacks research report on Mateon Therapeutics (MATN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related stocks with our FREE daily email newsletter.